Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPPEREIRA-BARRETTO, Antonio Carlos2016-02-112016-02-112015ADVANCES IN THERAPY, v.32, n.10, p.906-919, 20150741-238Xhttps://observatorio.fm.usp.br/handle/OPI/12645Heart failure has seen a number of therapeutic advances in recent years. Despite this, heart failure is still related to increasing rates of morbidity, repeated hospitalizations, and mortality. Ivabradine is a recent treatment option for heart failure. It has a mode of action that includes reduction in heart rate, and leads to improvement in outcomes related to heart failure mortality and morbidity, as demonstrated by the results of the SHIFT trial in patients with systolic heart failure, functional classes II and III on the NewYork Heart Association classification, and left ventricular ejection fraction B35%. These results are intriguing since many heart failure drugs reduce heart rate without such benefits, or with quite different effects, making it more difficult to understand the novelty of ivabradine in this setting. Many of the drugs used in heart failure modify heart rate, but most have other pathophysiological effects beyond their chronotropic action, which affect their efficacy in preventing morbidity and mortality outcomes. For instance, heart rate reduction at rest or exercise with ivabradine prolongs diastolic perfusion time, improves coronary blood flow, and increases exercise capacity. Another major difference is the increase in stroke volume observed with ivabradine, which may underlie its beneficial cardiac effects. Finally, there is mounting evidence from both preclinical and clinical studies that ivabradine has an anti-remodeling effect, improving left ventricular structures and functions. All together, these mechanisms have a positive impact on the prognosis of ivabradine-treated patients with heart failure, making a compelling argument for use of ivabradine in combination with other treatments. Funding: Servier.engrestrictedAccessCardiologyHeart failureHeart rateIvabradineMorbidityMortalityStroke volumeinduced myocardial-ischemiadiastolic perfusion timecoronary-artery-diseaseleft-ventricular massrate reductionexercise capacityejection fractioninfarcted ratsbeta-blockadeeuropean-societyarticleCopyright SPRINGER10.1007/s12325-015-0257-6Medicine, Research & ExperimentalPharmacology & Pharmacy1865-8652